Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor β antibody and interleukin-2

Journal of Immunotherapy

Volumn 19, Issue 3, 1996, Pages 169-175

  Wojtowicz Praga, Slawomir ^a   Verma, Udit M ^a   Wakefield, Lalage ^c   Esteban, Jose M ^b   Hartmann, Dan ^b   Mazumder, Amitabha ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

1L 2; Cancer; Cytokines; Immunosuppression; Melanoma; Metastasis; TGF

Indexed keywords

INTERLEUKIN 2; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CONTROLLED STUDY; EXTRACTION; FEMALE; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG METASTASIS; MELANOMA B16; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; IMMUNOTHERAPY; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030036344     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199605000-00001     Document Type: Article

References (24)

1. Glick AB, Lee MM, Darwiche N, Kulkarni AB, Karlsson S, Yuspa SH. Targeted deletion of the TGF-beta 1 gene causes rapid progression to squamous cell carcinoma. Genes Dev 1994;8:2429-40.
2. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. J Clin Invest 1993;92:2569-76.
3. Arteaga CL, Carty-Dugger T, Moses H, Hurd S, Pietenpol J. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Diff 1993;4:193-201.
4. Ruscetti FW, Dubois CM, Jacobsen SE, Keller JR. Transforming growth factor beta and interleukin-1: a paradigm for opposing regulation of hemopoiesis. Baillieres Clin Haematol 1992;5:703-21.
5. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD. Inhibition of tumor specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res 1992;52:1386-92.
6. Geller RL, Smyth MJ, Strobl SL, et al. Generation of lymphokine activated killer activity in T cells: possible regulatory circuits. J Immunol 1991;146:3280-8.
7. Blanckaert VD, Schelling ME, Elstad CA, Meadows GG. Differential growth factor production, secretion and response by high and low metastatic variants of B16BL6 melanoma. Cancer Res 1993;53:4075-81.
8. Ioannides CG, Whiteside TL. Short analytical review: T-cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin Immunol Immunopathol 1993;66:91-106.
9. Tsukuda M, Mochimatsu I, Sakumoto M, Furukawa S. Autologous tumor cell killing activity of tumor-associated lymphocytes in patients with head and neck carcinomas. Biotherapy 1993;6:155-61.
10. Schwartzentruber DJ, Stetler-Stevenson M, Rosenberg SA, Topalian SL. Tumor infiltrating lymphocytes derived from select B-cell lymphomas secrete GM-CSF and TNF alpha in response to autologous tumor stimulation. Blood 1993;82:1204-11.
11. Nouri AM, Bergbaum A, Lederer E, Crosby D, Shamsa A, Oliver RT. Paired tumor infiltrating lymphocyte (TIL) and tumor cell line from bladder cancer: a new approach to study tumor immunology in vitro. Eur J Cancer 1991;27:608-12.
12. Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J Immunother 1992;12:1-12.
13. Charak B, Agah R, Mazumder A. Synergism of IL-2 and cyclosporine in induction of a graft versus tumor effect without graft versus host disease after syngeneic bone marrow transplantation. Blood 1992;79:179-99.
14. Rohr von A, Thatcher N. Clinical applications of interleukin-2. Prog Growth Factor Res 1992;4:229-46.
15. Lucas C, Bald LN, Fendly BM, et al. The autocrine production of TGF-beta 1 during lymphocyte activation: a study with a monoclonal antibody-based ELISA. J Immunol 1990;145:1415-22.
16. Charak BS, Sadowski RM, Mazumder A. Anti-tumor effect of interferon plus cyclosporine A following chemotherapy for disseminated melanoma. Cancer Res 1992;52:6482-6.
17. Wakefield LM, Letterio JJ, Chen T, et al. Transforming growth factor beta-1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1995;1:129-36.
18. Gridley DS, Sura SS, Uhm JR, Lin CH, Kettering JD. Effects of anti-transforming growth factor-beta antibody and interleukin-2 in tumor-bearing mice. Cancer Biother 1993;8:159-70.
19. Mao XW, Kettering JD, Gridley DS. Immunotherapy with low dose interleukin-2 and anti-transforming growth factor-beta antibody in a murine tumor model. Cancer Biother 1994;9:317-27.
20. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993;328:1592-8.
21. Eder IE, Stenzl A, Cronauer MV, Bartsch G, Klocker H. Transforming growth factor beta 1 and beta 2 and basic fibroblast growth factor in serum and urine from patients with bladder cancer. Proc Am Assoc Cancer Res 1995;31:245.
22. Shirai Y, Kawata S, Ito N, et al. Elevated levels of plasma transforming growth factor β in patients with hepatocellular carcinoma. Jpn J Cancer Res 1992;83:676-9.
23. Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995;92:2572-6.
24. Assoian RK, Sporn MB. Type β transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol 1986;102:1217-23.